Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...
CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...
Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, also recognized as Wuhan...
Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the...
Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation
Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator,...
Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...
MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III...
National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...
Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs
Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...
China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030
The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...
Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...
NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs
The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...
BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments
China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE
Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...